Table 3 Antiretroviral therapy use, adherence, immunological and virological markers by time since HAART initiation stratified by HIV RNA ⩾ 300 or <300 copies/ml at the fifth year after HAART initiation.

Years from HAART initiation	HIV RNA <300 copies/ml at fifth year after HAART (n = 517)				HIV RNA ⩾300 copies/ml at fifth year after HAART (n = 423)
	⩾−1 and <0	⩾0 and <1	⩾1 and <3	⩾3 and <5	⩾−1 and <0	⩾0 and <1	⩾1 and <3	⩾3 and <5
Number of person visits	913	887	1660	1753	757	705	1307	1332
NRTI, %
= 0	31	0	0	0	26	0	0	0
= 1	17	2	9	9	22	4	12	10
⩾2	52	98	91	91	52	96	88	90
PI, %
= 0	95	12	16	41	93	9	16	31
= 1	4	76	68	43	7	75	61	45
⩾2	1	12	16	16	<1	16	23	24
NNRTI, %
= 0	>99	83	68	54	99	85	65	54
= 1	<1	17	32	45	1	15	34	44
⩾2	0	0	<1	1	0	0	1	2
Adherence, %		n = 125	n = 1207	n = 1740		n = 77	n = 902	n = 1317
100	NA	39	42	40	NA	36	36	34
95–99	NA	40	45	47	NA	38	39	41
75–94	NA	15	9	12	NA	22	18	17
<75	NA	6	4	1	NA	4	7	8
CD4 (cells/mm3)
Median	313	386	470	528	249	318	352	339
IQR	178–461	246–550	306–656	351–728	150–400	199–461	213–532	196–541
HIV RNA (copies/ml)
Median	13244	115	<80	<80	28000	2554	3500	4365
IQR	3744–64000	<80–1551	<50–505	<50–80	5500–110000	200–19000	320–23000	690–23195